GENMAB A/S

Over the last 90 days, Genmab A/S (GNMSF) has reported zero cyber incidents and zero red-flag 8-K filings—no bankruptcy warnings, restatements, or officer departures in our detection window. However, low signal in a 90-day window does not mean low risk; the biotech sector carries sector-specific pressures around clinical trials, regulatory decisions, and capital structure that require deeper context. The full $49 Report extends analysis to 12 months of filing history, adds dilution risk scoring, financing trajectory review, and AI-driven signals on cash burn and pipeline risk. The full $49 Report adds shareholder dilution estimates, 12-month 8-K context, and capital adequacy modeling for your investment thesis.